• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌和前列腺癌:更多的相似之处而非不同。

Breast and prostate cancer: more similar than different.

机构信息

Department of Anatomy & Developmental Biology, Monash University Clayton Campus, Melbourne 3800, Victoria, Australia.

出版信息

Nat Rev Cancer. 2010 Mar;10(3):205-12. doi: 10.1038/nrc2795. Epub 2010 Feb 11.

DOI:10.1038/nrc2795
PMID:20147902
Abstract

Breast cancer and prostate cancer are the two most common invasive cancers in women and men, respectively. Although these cancers arise in organs that are different in terms of anatomy and physiological function both organs require gonadal steroids for their development, and tumours that arise from them are typically hormone-dependent and have remarkable underlying biological similarities. Many of the recent advances in understanding the pathophysiology of breast and prostate cancers have paved the way for new treatment strategies. In this Opinion article we discuss some key issues common to breast and prostate cancer and how new insights into these cancers could improve patient outcomes.

摘要

乳腺癌和前列腺癌分别是女性和男性中最常见的两种侵袭性癌症。尽管这些癌症发生在解剖和生理功能上不同的器官中,但两者的发育都需要性腺类固醇,而且由此产生的肿瘤通常是激素依赖性的,并具有显著的潜在生物学相似性。对乳腺癌和前列腺癌病理生理学的许多最新研究进展为新的治疗策略铺平了道路。在这篇观点文章中,我们讨论了乳腺癌和前列腺癌的一些共同关键问题,以及对这些癌症的新认识如何改善患者的预后。

相似文献

1
Breast and prostate cancer: more similar than different.乳腺癌和前列腺癌:更多的相似之处而非不同。
Nat Rev Cancer. 2010 Mar;10(3):205-12. doi: 10.1038/nrc2795. Epub 2010 Feb 11.
2
The impact of transcription on metabolism in prostate and breast cancers.转录对前列腺癌和乳腺癌代谢的影响。
Endocr Relat Cancer. 2018 Sep;25(9):R435-R452. doi: 10.1530/ERC-18-0048. Epub 2018 May 14.
3
A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers.一种与部分乳腺癌和前列腺癌中激素非依赖性相关的基因转录特征。
BMC Genomics. 2007 Jun 28;8:199. doi: 10.1186/1471-2164-8-199.
4
Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives.激素依赖性乳腺癌和前列腺癌中甾体活性的药物调节:一些植物提取物衍生物的作用。
Int J Mol Sci. 2020 May 23;21(10):3690. doi: 10.3390/ijms21103690.
5
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.雄激素诱导前列腺癌和乳腺癌细胞凋亡的统一生物学。
Endocr Relat Cancer. 2018 Feb;25(2):R83-R113. doi: 10.1530/ERC-17-0416. Epub 2017 Nov 21.
6
Roles of Splicing Factors in Hormone-Related Cancer Progression.剪接因子在激素相关癌症进展中的作用。
Int J Mol Sci. 2020 Feb 25;21(5):1551. doi: 10.3390/ijms21051551.
7
Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.类固醇激素受体作为乳腺癌和前列腺癌治疗的靶点——最新进展、耐药机制及新方法
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. doi: 10.1016/j.jsbmb.2004.12.002. Epub 2005 Jan 28.
8
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.乳腺癌和前列腺癌中激素治疗耐药的机制与管理
Endocr Relat Cancer. 2005 Sep;12(3):511-32. doi: 10.1677/erc.1.01026.
9
Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.催乳素受体在乳腺癌和前列腺癌中的靶向治疗:旧挑战的新见解。
Pharmacol Ther. 2017 Nov;179:111-126. doi: 10.1016/j.pharmthera.2017.05.009. Epub 2017 May 23.
10
The biology of hormone refractory breast and prostate cancer: An NCI workshop report.激素难治性乳腺癌和前列腺癌的生物学特性:NCI 研讨会报告。
Cancer Biol Ther. 2009 Nov;8(21):1975-85. doi: 10.4161/cbt.8.21.9918. Epub 2009 Nov 26.

引用本文的文献

1
Cell Progression and Survival Functions of Enzymes Secreted in Extracellular Vesicles Associated with Breast and Prostate Cancers.与乳腺癌和前列腺癌相关的细胞外囊泡分泌的酶的细胞进展和存活功能
Cells. 2025 Mar 21;14(7):468. doi: 10.3390/cells14070468.
2
Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.对378例前列腺癌转移灶进行全基因组测序,揭示了错配缺陷的组织选择性及其潜在的治疗意义。
Genome Med. 2025 Mar 20;17(1):24. doi: 10.1186/s13073-025-01445-5.
3
Chemogenomics for steroid hormone receptors (NR3).

本文引用的文献

1
Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.雌激素受体-β在前列腺良性增生和癌中的凋亡激活是雄激素非依赖性的,并受 TNFα 介导。
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3123-8. doi: 10.1073/pnas.0905524107. Epub 2010 Feb 1.
2
Expression of androgen receptors in primary breast cancer.雄激素受体在原发性乳腺癌中的表达。
Ann Oncol. 2010 Mar;21(3):488-492. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.
3
Pten in stromal fibroblasts suppresses mammary epithelial tumours.
类固醇激素受体(NR3)的化学基因组学
Commun Chem. 2025 Feb 3;8(1):29. doi: 10.1038/s42004-025-01427-z.
4
Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance.质膜相关的ARAF凝聚物助长RAS相关的癌症耐药性。
Nat Chem Biol. 2025 Jan 27. doi: 10.1038/s41589-024-01826-8.
5
Harnessing sample preparation for RNA-sequencing toward a reliable bioinformatics analysis.利用RNA测序的样本制备进行可靠的生物信息学分析。
J Transl Med. 2024 Sep 16;22(1):846. doi: 10.1186/s12967-024-05585-x.
6
Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.女性性别与胃肠胰神经内分泌肿瘤生存改善相关。
J Surg Res. 2024 Oct;302:53-63. doi: 10.1016/j.jss.2024.07.012. Epub 2024 Jul 30.
7
ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.ONECUT2是从腔面型到基底样型乳腺癌可塑性的可药物作用驱动因子。
Cell Oncol (Dordr). 2025 Feb;48(1):83-99. doi: 10.1007/s13402-024-00957-3. Epub 2024 May 31.
8
Joint Representation Learning for Retrieval and Annotation of Genomic Interval Sets.用于基因组区间集检索和注释的联合表示学习
Bioengineering (Basel). 2024 Mar 8;11(3):263. doi: 10.3390/bioengineering11030263.
9
Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.基于单细胞测序分析,AR 调控的 AFF3 丢失导致前列腺癌进展,并通过下调 ACSL4 降低铁死亡敏感性。
Apoptosis. 2024 Oct;29(9-10):1679-1695. doi: 10.1007/s10495-024-01941-w. Epub 2024 Mar 13.
10
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.用于治疗肺癌的药物偶联物:从药物发现到临床实践
Exp Hematol Oncol. 2024 Mar 1;13(1):26. doi: 10.1186/s40164-024-00493-8.
基质成纤维细胞中的Pten抑制乳腺上皮肿瘤。
Nature. 2009 Oct 22;461(7267):1084-91. doi: 10.1038/nature08486.
4
Nuclear receptor coregulators in cancer biology.癌症生物学中的核受体共调节因子。
Cancer Res. 2009 Nov 1;69(21):8217-22. doi: 10.1158/0008-5472.CAN-09-2223. Epub 2009 Oct 20.
5
Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.乳腺癌辅助激素治疗与对侧乳腺癌激素受体特异性亚型的风险
Cancer Res. 2009 Sep 1;69(17):6865-70. doi: 10.1158/0008-5472.CAN-09-1355. Epub 2009 Aug 25.
6
Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.托瑞米芬高剂量治疗在芳香化酶抑制剂治疗后复发患者的临床疗效。
Breast Cancer. 2010 Oct;17(4):254-60. doi: 10.1007/s12282-009-0148-2. Epub 2009 Aug 15.
7
Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.芬兰前列腺癌筛查试验中使用非那雄胺和α受体阻滞剂的人群的前列腺癌发病率。
Br J Cancer. 2009 Sep 1;101(5):843-8. doi: 10.1038/sj.bjc.6605188. Epub 2009 Aug 4.
8
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.雄激素受体抑制雌激素受体α活性并在乳腺癌中具有预后价值。
Cancer Res. 2009 Aug 1;69(15):6131-40. doi: 10.1158/0008-5472.CAN-09-0452. Epub 2009 Jul 28.
9
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.来自两项关于用西妥昔单抗进行活性细胞免疫疗法治疗晚期前列腺癌的3期随机、双盲、安慰剂对照试验的综合数据。
Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.
10
An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.一项开放、随机、多中心、3 期临床试验,比较了两种他莫昔芬方案预防比卡鲁胺单药治疗前列腺癌患者引起的男性乳房发育的疗效。
Eur Urol. 2010 Feb;57(2):238-45. doi: 10.1016/j.eururo.2009.05.019. Epub 2009 May 19.